Tests of new Merck painkiller criticized
14th Nov 2006, 12:11 GMT
The first published studies of Arcoxia, the drug that Merck & Co. hopes will take the place of its withdrawn painkiller Vioxx, are getting mixed reviews from doctors, some of whom say the results do not make a case for approving the medicine.
Tests of new Merck painkiller criticized related news:
- Docs Give Merck Painkiller Acroxia Mixed Reviews — FOXNews.com
- Merck: Arcoxia heart risk same as Voltaren — United Press International - Health Business
- Merck: New pain killer safer than Vioxx — Business and financial news - CNNMoney.com
- Merck says new drug is safer than Vioxx — Cardiology News from StratCenter.com
- Merck: New pain drug safer than Vioxx — Financial news of the day - CNNMoney.com
- Merck: New drug safer than Vioxx — Business and financial news - CNNMoney.com
- Results Mixed on Merck's New Painkiller — LancasterOnline - Health
- Results mixed on Merck's new painkiller (AP) — Yahoo! News: Health News
- Results mixed on Merck's new painkiller (Associated Press) — Yahoo! Health: Health News
- Results on Merck's new painkiller draw mixed reviews — azcentral.com | business